Fifth Circuit rejects PhRMA's challenge to Medicare drug-price negotiation, ending pharma's first wave of IRA litigation.

In the latest in a string of setbacks in biopharma’s efforts to fight Medicare drug price negotiations, a lawsuit from the industry’s top lobbying group has been rejected at the…

Fifth Circuit rejects PhRMA's challenge to Medicare drug-price negotiation, ending pharma's first wave of IRA litigation.